Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1053691/000143774919009285/dffn20190331_10q.htm
SEC Filings
DFFN Annual Reports
DFFN Quarterly Reports
10-Q Quarterly Report August 2023
10-Q Quarterly Report May 2023
10-Q Quarterly Report November 2022
10-Q Quarterly Report August 2022
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report August 2023
10-Q Quarterly Report May 2023
10-Q Quarterly Report November 2022
10-Q Quarterly Report August 2022
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
DFFN Corporate News
Accountant Change
Bylaw Change
Change in Assets
Change in Control
Event for Officers
Financial Exhibit
Other Events
Regulated Disclosure
Security Holders Change
Vote of Security Holders August 2023
Financial Exhibit
Other Events August 2023
Financial Exhibit
Other Events August 2023
Other Events August 2023
Financial Exhibit
Other Events August 2023
Event for Officers
Financial Exhibit
New Agreement July 2023
Event for Officers
Financial Exhibit June 2023
Ending Agreement
Event for Officers
Financial Exhibit
New Agreement May 2023
Financial Exhibit
Other Events May 2023
Financial Exhibit
Other Events May 2023
Accountant Change
Bylaw Change
Change in Assets
Change in Control
Event for Officers
Financial Exhibit
Other Events
Regulated Disclosure
Security Holders Change
Vote of Security Holders
Bylaw Change
Change in Assets
Change in Control
Event for Officers
Financial Exhibit
Other Events
Regulated Disclosure
Security Holders Change
Vote of Security Holders
August 2023
Financial Exhibit
Other Events
Other Events
August 2023
Financial Exhibit
Other Events
Other Events
August 2023
Other Events
August 2023
Financial Exhibit
Other Events
Other Events
August 2023
Event for Officers
Financial Exhibit
New Agreement
Financial Exhibit
New Agreement
July 2023
Event for Officers
Financial Exhibit
Financial Exhibit
June 2023
Ending Agreement
Event for Officers
Financial Exhibit
New Agreement
Event for Officers
Financial Exhibit
New Agreement
May 2023
Financial Exhibit
Other Events
Other Events
May 2023
Financial Exhibit
Other Events
Other Events
May 2023
DFFN Merger Prospectus
425 Merger Prospectus August 2023
425 Merger Prospectus August 2023
425 Merger Prospectus August 2023
425 Merger Prospectus August 2023
425 Merger Prospectus July 2023
425 Merger Prospectus May 2023
425 Merger Prospectus May 2023
425 Merger Prospectus May 2023
425 Merger Prospectus April 2023
425 Merger Prospectus March 2023
425 Merger Prospectus August 2023
425 Merger Prospectus August 2023
425 Merger Prospectus August 2023
425 Merger Prospectus August 2023
425 Merger Prospectus July 2023
425 Merger Prospectus May 2023
425 Merger Prospectus May 2023
425 Merger Prospectus May 2023
425 Merger Prospectus April 2023
425 Merger Prospectus March 2023
DFFN Registration of Securities
Last10K.com | 10-Q Quarterly Report Thu May 09 2019
Document And Entity Information - shares | 3 Months Ended | |
|---|---|---|
Mar. 31, 2019 | May 08, 2019 | |
| Document Information [Line Items] | ||
| Entity Registrant Name | Diffusion Pharmaceuticals Inc. | |
| Entity Central Index Key | 0001053691 | |
| Trading Symbol | dffn | |
| Current Fiscal Year End Date | --12-31 | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Current Reporting Status | Yes | |
| Entity Emerging Growth Company | false | |
| Entity Small Business | true | |
| Entity Common Stock, Shares Outstanding (in shares) | 3,379,345 | |
| Document Type | 10-Q | |
| Document Period End Date | Mar. 31, 2019 | |
| Document Fiscal Year Focus | 2019 | |
| Document Fiscal Period Focus | Q1 | |
| Amendment Flag | false |
View differences made from one quarter to another to evaluate Diffusion Pharmaceuticals Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Diffusion Pharmaceuticals Inc..
Assess how Diffusion Pharmaceuticals Inc.'s management team is paid from their Annual Proxy
Diffusion Pharmaceuticals Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Document And Entity Information
Condensed Consolidated Balance Sheets (Current Period Unaudited)
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)
Condensed Consolidated Statement Of Changes In Convertible Preferred Stock And Stockholders' Equity (Unaudited)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Note 1 - Organization And Description Of Business
Note 1 - Organization And Description Of Business (Details Textual)
Note 2 - Liquidity
Note 3 - Basis Of Presentation And Summary Of Significant Accounting Policies
Note 3 - Basis Of Presentation And Summary Of Significant Accounting Policies (Details Textual)
Note 3 - Basis Of Presentation And Summary Of Significant Accounting Policies (Tables)
Note 3 - Basis Of Presentation And Summary Of Significant Accounting Policies - Outstanding Dilutive Securities (Details)
Note 4 - Accrued Expenses And Other Current Liabilities
Note 4 - Accrued Expenses And Other Current Liabilities (Tables)
Note 4 - Accrued Expenses And Other Current Liabilities - Summary Of Accrued Expenses (Details)
Note 5 - Stockholders' Equity And Common Stock Warrants
Note 5 - Stockholders' Equity And Common Stock Warrants (Details Textual)
Note 5 - Stockholders' Equity And Common Stock Warrants (Tables)
Note 5 - Stockholders' Equity And Common Stock Warrants - Warrants Outstanding To Acquire Shares Of Its Common Stock (Details)
Note 6 - Stock-Based Compensation
Note 6 - Stock-Based Compensation (Details Textual)
Note 6 - Stock-Based Compensation (Tables)
Note 6 - Stock-Based Compensation - Fair Value Assumptions (Details)
Note 6 - Stock-Based Compensation - Stock Option Activity (Details)
Note 6 - Stock-Based Compensation - Stock-Based Compensation Expense (Details)
Note 7 - Commitments And Contingencies
Note 7 - Commitments And Contingencies (Details Textual)
Note 7 - Commitments And Contingencies (Tables)
Note 7 - Commitments And Contingencies - Future Minimum Rental Payments (Details)
Significant Accounting Policies (Policies)
Material Contracts, Statements, Certifications & more
Diffusion Pharmaceuticals Inc. provided additional information to their SEC Filing as exhibits
Ticker: DFFN
CIK: 1053691
Form Type: 10-Q Quarterly Report
Accession Number: 0001437749-19-009285
Submitted to the SEC: Thu May 09 2019 4:01:35 PM EST
Accepted by the SEC: Thu May 09 2019
Period: Sunday, March 31, 2019
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
SEC.gov
Bookmark the Permalink: https://last10k.com/sec-filings/dffn/0001437749-19-009285.htm
Stock Screener
View trending companies on
View trending companies on
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...